TWD 72.7
(-0.41%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -705.97 Million TWD | -44.39% |
2022 | -488.94 Million TWD | -2330.97% |
2021 | -20.11 Million TWD | 72.89% |
2020 | -74.2 Million TWD | 84.78% |
2019 | -487.39 Million TWD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q2 | -92.32 Million TWD | 90.9% |
2024 Q1 | -1.01 Billion TWD | -43.76% |
2023 Q4 | -705.97 Million TWD | -168.04% |
2023 FY | -705.97 Million TWD | -44.39% |
2023 Q1 | -698.79 Million TWD | -42.04% |
2023 Q3 | -263.38 Million TWD | -34.03% |
2023 Q2 | -196.5 Million TWD | 71.88% |
2022 Q4 | -491.98 Million TWD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Allied Biotech Corporation | 178.11 Million TWD | 496.364% |
GeneFerm Biotechnology Co., Ltd. | 31.92 Million TWD | 2311.289% |
Easywell Biomedicals, Inc. | 123.43 Million TWD | 671.932% |
Synmosa Biopharma Corporation | 1.52 Billion TWD | 146.406% |
Orient EuroPharma Co., Ltd. | 3.1 Billion TWD | 122.727% |
Center Laboratories, Inc. | 3.91 Billion TWD | 118.014% |
Tien Liang BioTech Co., Ltd. | -57.55 Million TWD | -1126.59% |
Orient Pharma Co., Ltd. | 633.6 Million TWD | 211.422% |
InnoPharmax Inc. | -17.85 Million TWD | -3853.276% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | -926.77 Million TWD | 23.825% |
Excelsior Biopharma Inc. | -212.51 Million TWD | -232.204% |
DV Biomed Co., Ltd. | 160.7 Million TWD | 539.313% |
Foresee Pharmaceuticals Co., Ltd. | -781.42 Million TWD | 9.655% |
Handa Pharmaceuticals, Inc. | -653.8 Million TWD | -7.979% |
UniPharma Co., Ltd. | -68.36 Million TWD | -932.627% |
Anxo Pharmaceutical Co., Ltd. | 492.4 Million TWD | 243.373% |
Alar Pharmaceuticals Inc. | -738.05 Million TWD | 4.346% |
Winston Medical Supply Co., Ltd. | -191.81 Million TWD | -268.06% |
Mercury Biopharmaceutical Corporation | -1.94 Million TWD | -36196.967% |
Bioray Biotech Co., Ltd | -27.23 Million TWD | -2492.45% |
TSH Biopharm Corporation Limited | -568.74 Million TWD | -24.129% |